What Is the Best Probiotic With GR-1 and RC-14?

The two probiotic strains with the strongest clinical track record for women’s urogenital health are Lacticaseibacillus rhamnosus GR-1 and Limosilactobacillus reuteri RC-14, a pairing studied in dozens of trials over more than two decades. GR-1 is widely regarded as the most researched probiotic strain for women’s health.¹ Finding a product that actually delivers these strains at the dose and quality used in research, though, requires knowing what to look for and what the evidence really shows.

Why GR-1 and RC-14 Are Paired Together

These two strains were selected and developed as a team because they complement each other. GR-1 is especially good at adhering to urogenital tissue, while RC-14 produces antimicrobial compounds that help suppress harmful bacteria. Researchers identified both strains for their ability to inhibit the growth and adhesion of urogenital pathogens, and the earliest clinical work established that the combination could colonize the vagina even when taken by mouth. That was a pivotal discovery: the strains survive stomach acid and bile, travel through the intestine, and ascend to the vaginal tract without any direct vaginal application.² This oral-to-vaginal migration route is what makes the combination practical as a daily capsule rather than a suppository.

When researchers tested oral intake of GR-1 and RC-14 in healthy women, they found that both strains could be detected in vaginal samples, and in some cases remained for several months after supplementation stopped.² A separate safety study confirmed that the strains survive gastrointestinal transit without triggering systemic immune or inflammatory responses, with immune markers like IL-6 and IFN-γ staying within normal ranges.³

What the Clinical Trials Say About Bacterial Vaginosis

Bacterial vaginosis (BV) is the condition where GR-1 and RC-14 have been studied most intensively, and the results are a mix of impressive wins and some notable disappointments depending on the study design and population.

The strongest evidence comes from trials that combine the probiotic with standard antibiotic treatment. In a randomized, double-blind trial, women taking oral metronidazole plus GR-1 and RC-14 for 30 days had an 88% cure rate, compared to 40% in the group receiving metronidazole plus placebo.⁴ That is a substantial difference. High counts of Lactobacillus were recovered from the vaginas of 96% of probiotic-treated women at day 30, compared to just over half of controls, suggesting the probiotics helped restore a healthier microbial environment.⁴

A separate trial pairing GR-1 and RC-14 with a single dose of tinidazole (another antibiotic used for BV) found a similar pattern: about 88% cure rate in the probiotic group versus 50% in the placebo group by day 28, with a significantly higher proportion of women showing normal vaginal microbiota by Gram-stain scoring.⁵

One small but striking trial tested the strains as a standalone treatment, without any antibiotic. It reported cure of BV in 90% of probiotic-treated women by day 30, compared to roughly half of the metronidazole-treated comparison group.⁶ That result attracted attention because it suggested the probiotic alone might outperform the antibiotic gel. However, the study was small (40 women), and the finding has not been consistently replicated in larger populations.

A larger trial in Chinese women, for instance, found no significant difference between metronidazole alone and metronidazole plus oral GR-1/RC-14, with 30-day cure rates around 58-60% in both groups.⁷ At 90 days, cure rates dropped further and still showed no clear advantage for the probiotic group. The researchers suggested that population differences or variations in vaginal microbiome composition may play a role in these divergent outcomes.

A meta-analysis pooling data from multiple randomized trials found that overall, adding probiotics to BV treatment significantly improved cure rates, with high-quality studies showing an even larger benefit and particularly strong results in European populations and with shorter follow-up periods.⁸ The takeaway: GR-1/RC-14 looks most effective as a partner to antibiotic therapy, not necessarily as a replacement, and results may vary across populations.

Evidence for Yeast Infections

The picture for vulvovaginal candidiasis (yeast infections) follows a similar pattern: the combination works best alongside antifungal medication rather than solo. In a trial of 55 women diagnosed with yeast infections, those who received a single dose of fluconazole followed by four weeks of daily GR-1/RC-14 capsules had significantly better outcomes than those who got fluconazole plus placebo. About 10% of the probiotic group still had symptoms with positive yeast cultures at four weeks, compared to roughly 39% of the placebo group.⁹

Not every trial agrees. A study of 50 women with vaginal discharge found no difference in cure rates or patient satisfaction between the probiotic and placebo groups after four weeks of treatment, with both groups hovering around 56-60% cure rates. The researchers noted their study was likely underpowered to detect a meaningful difference.¹⁰ Small sample sizes are a recurring limitation in this field. The evidence tilts positive for yeast infections as adjunctive therapy, but it is not as robust as the BV data.

What About Urinary Tract Infections?

UTI prevention is the original context for GR-1’s development, since it was first isolated from the urethra of a healthy woman. The logic is straightforward: if you can maintain a healthy Lactobacillus population in the urogenital tract, pathogenic bacteria have a harder time gaining a foothold. Reviews of the literature suggest that probiotic interventions with these strains show some efficacy for both treatment and prevention of urogenital infections, though the evidence base for UTIs specifically is thinner than for BV.¹¹

A pilot trial in girls with spina bifida who depended on catheterization, a population at very high risk for UTIs, tested daily oral doses of GR-1 and RC-14 to see whether the strains could reduce infection rates in this vulnerable group.¹² While that trial was small and exploratory, it underscores the range of populations being investigated. For routine UTI prevention in otherwise healthy women, the data is encouraging but not yet definitive enough to replace established strategies like post-coital voiding or, in severe cases, low-dose antibiotic prophylaxis. The strains are more often considered a complement to those approaches.

Dose and Duration Used in Research

If you are shopping for a probiotic and want to match what the research actually tested, the dose matters. Most clinical trials used one billion colony-forming units (CFU) of each strain per capsule, taken once or twice daily, for a total daily dose of about two to four billion CFU combined.⁴ Some trials used higher counts. A study in pregnant women used capsules containing 2.5 billion CFU of each strain, totaling five billion CFU per capsule, with freeze-dried organisms in gelatin capsules using simple fillers like dextrose and potato starch.¹³ A pediatric pilot trial similarly used two billion CFU of each strain daily.¹²

Treatment duration in trials ranged from four weeks to several months. For BV, the typical protocol ran 28 to 30 days, often starting simultaneously with antibiotic therapy. For ongoing preventive use, some protocols extended to 12 weeks or more. The key point for consumers: a product advertising 50 billion CFU of mixed strains is not necessarily better than one delivering two to five billion of specifically GR-1 and RC-14. Strain identity matters far more than raw CFU numbers when the evidence base is strain-specific.

What to Look for on the Label

Probiotic labeling can be a minefield. These strains have gone through name changes: GR-1 was originally called Lactobacillus rhamnosus GR-1 and is now officially Lacticaseibacillus rhamnosus GR-1. RC-14 was originally Lactobacillus fermentum RC-14 and is now Limosilactobacillus reuteri RC-14.¹ A legitimate product may use either the old or new genus names, but it should always list the strain designation: GR-1 and RC-14. If a label says “Lactobacillus rhamnosus” without specifying the strain, you have no way of knowing whether you are getting GR-1 or one of the hundreds of other L. rhamnosus strains, many of which have completely different properties.

Researchers who have worked on bringing these strains to market have emphasized that consumer-facing information should state the specific strain attributes and reference the peer-reviewed research supporting them.¹⁴ That means a credible product will typically name the strain codes on the label or supplement facts panel and, ideally, reference the body of clinical research. Products that bury strain identity in vague language like “proprietary blend” or list only genus and species without strain codes are not giving you enough information to verify what you are buying.

A few practical checkboxes when evaluating a product:

Strain codes listed: Both “GR-1” and “RC-14” should appear somewhere on the packaging or supplement facts, not just genus/species names.
CFU guarantee at expiration: The CFU count should be guaranteed through the end of shelf life, not just at the time of manufacture. Probiotics lose viability over time, and a product that starts with two billion CFU per capsule may deliver far less by the time you take it if storage conditions are not ideal.
Reasonable dose: Look for at least one billion CFU of each strain per daily serving, consistent with the clinical literature.
Simple excipients: Research capsules typically use straightforward fillers like dextrose, potato starch, and cellulose.¹³ A laundry list of additives is not necessarily harmful, but it can signal a product prioritizing marketing over formulation quality.

Using GR-1 and RC-14 Alongside Antibiotics

One of the most common questions is whether you can take these probiotics at the same time as antibiotics, or whether the antibiotics will just kill the probiotic bacteria. The trials that showed the largest benefits actually administered GR-1 and RC-14 concurrently with antibiotics, starting both on day one.⁴ The probiotic continued for 30 days while the antibiotic course was typically seven days, so the probiotics had an extended window to recolonize the vaginal environment after the antibiotic finished its work.

The practical lesson from this design is that you do not need to wait until an antibiotic course ends before starting the probiotic. The data suggests starting them together and continuing the probiotic well beyond the antibiotic course is the approach most likely to improve outcomes. That said, spacing them a couple of hours apart during the overlap days is a reasonable precaution, since direct contact between a concentrated antibiotic and the probiotic organisms in your gut could reduce initial survival, even if the clinical trials did not explicitly test this timing detail.

Safety During Pregnancy

Pregnancy is a period when BV and yeast infections are especially concerning, since both have been linked to complications like preterm delivery. GR-1 and RC-14 have been studied in pregnant women. One clinical protocol administered two capsules daily (each containing over a million bacilli of each strain) for six to 12 weeks, up to roughly the 24th or 25th week of pregnancy, specifically to investigate whether the probiotics could help prevent preterm delivery associated with intrauterine infection.¹⁵ Another trial gave pregnant women capsules containing 2.5 billion CFU of each strain and monitored vaginal microbiota and immune markers.¹³

The safety data from oral administration studies, including in non-pregnant adults, has been reassuring: the strains do not provoke systemic immune activation, with no notable increases in immunoglobulins and inflammatory cytokines remaining within normal ranges.³ Still, pregnant women should discuss any new supplement with their healthcare provider, particularly in the first trimester when the evidence base is slimmest.

Perceived Benefits Beyond What the Numbers Capture

Clinical trials typically measure cure rates using laboratory scores and pathogen cultures, but how a person feels day-to-day matters too. In a trial of 64 healthy women, about 30% of those taking GR-1 and RC-14 reported a perceived improvement in vaginal health, compared to 12% on placebo. That difference did not reach statistical significance in the study’s formal analysis, and there was no measurable difference between groups in vaginal itchiness, odor, or impact on intimate activity.¹⁶ The trial did confirm that the probiotics significantly altered vaginal flora composition, even in women who did not have active infections. Two women on placebo actually reported feeling worse in terms of vaginal discomfort, while none in the probiotic group did.

This hints at something the hard numbers sometimes miss: even when cure rate differences are modest, maintaining a Lactobacillus-dominant vaginal environment through supplementation may provide a background sense of well-being that is real but difficult to capture in traditional endpoints. It also helps explain why many women report feeling better on these probiotics even when they do not have a diagnosed infection.

How GR-1 Is Genetically Different From Other Lactobacillus Strains

Not all Lactobacillus rhamnosus strains are interchangeable, and the genomic evidence explains why. The most famous strain of L. rhamnosus is GG, widely used in gut health products. GR-1 and GG share a species name but differ in ways that matter for where they work best. GG uses specific hair-like structures called SpaCBA pili to cling to intestinal mucus and gut lining cells. GR-1 lacks the genes for these pili entirely, which genomic analysis has confirmed.¹⁷ In adhesion tests, GR-1 behaves like a mutant version of GG that has had its pili genes deleted: it sticks poorly to intestinal cells but uses a different strategy for vaginal tissue.

That different strategy involves a lectin-like protein, annotated as Llp1, which GR-1 uses to bind specifically to vaginal epithelial cells and inhibit urogenital pathogens.¹⁸ This is a clear example of tissue-specific adaptation: GG is optimized for the gut, GR-1 is optimized for the urogenital tract. Buying a generic “L. rhamnosus” probiotic designed for digestive health and expecting vaginal benefits is a biological mismatch. The strain code is not just a marketing detail; it reflects genuinely different biology.

When the Evidence Gets Thin

For all the research behind GR-1 and RC-14, there are real gaps. Most of the positive BV trials come from African populations, and the large Chinese trial that showed no benefit raises the question of whether the strains work differently across ethnic or geographic populations with different baseline vaginal microbiome compositions.⁷ The meta-analysis that found overall benefit also flagged that results were strongest in European populations and with shorter follow-up, suggesting the probiotics may help in the short term but that their advantage narrows over several months.⁸

The UTI prevention data, while biologically plausible and supported by mechanistic studies, still lacks the large, definitive randomized trials that would make it a slam-dunk recommendation. And while the strains have been tested in women living with HIV, the published evidence from that population is limited in what it can tell us about cure rates versus immune-related confounders. If you are considering GR-1 and RC-14 for any condition beyond BV as an adjunct to antibiotics, you are stepping into territory where the science is suggestive but not settled. That does not mean it is worthless; it means your expectations should be calibrated accordingly.

Manufacturing Reliability and What Can Go Wrong

Probiotic quality control has been a persistent industry problem. Researchers have noted that bringing strains like GR-1 and RC-14 to market requires reliable production and delivery vehicles.¹⁴ Freeze-dried bacteria in capsules are sensitive to heat and moisture. A product stored in a hot warehouse or shipped without temperature control may arrive with substantially fewer viable organisms than the label claims. Some manufacturers address this by overfilling capsules at production so the count still meets the label guarantee at expiration, while others specify refrigeration.

Because probiotics are regulated as dietary supplements in most countries rather than as drugs, the barrier to market is lower and the enforcement of label accuracy is inconsistent. Independent testing labs have repeatedly found products that contain fewer organisms than claimed, wrong species, or additional unlisted organisms. For a strain-specific product like one containing GR-1 and RC-14, this matters more than it does for a generic multi-strain probiotic, because the entire value proposition depends on those exact strains being present and alive. Looking for products that carry third-party verification or that come from manufacturers with documented quality control practices is one of the few practical safeguards available to consumers.

1
Trends in Microbiology. Lacticaseibacillus rhamnosus GR-1: a benchmark probiotic from women’s health to diverse applications
2
FEMS Immunology & Medical Microbiology. Oral probiotics can resolve urogenital infections
3
International Dairy Journal. Oral administration of the probiotic combination Lactobacillus rhamnosus GR-1 and L. fermentum RC-14 for human intestinal applications
4
Microbes and Infection. Augmentation of antimicrobial metronidazole therapy of bacterial vaginosis with oral probiotic Lactobacillus rhamnosus GR-1 and Lactobacillus reuteri RC-14: randomized, double-blind, placebo controlled trial
5
PubMed Central. Improved cure of bacterial vaginosis with single dose of tinidazole (2 g), Lactobacillus rhamnosus GR-1, and Lactobacillus reuteri RC-14: a randomized, double-blind, placebo-controlled trial
6
PubMed. Clinical study comparing probiotic Lactobacillus GR-1 and RC-14 with metronidazole vaginal gel to treat symptomatic bacterial vaginosis
7
PubMed Central. Probiotic Lacticaseibacillus rhamnosus GR-1 and Limosilactobacillus reuteri RC-14 as an Adjunctive Treatment for Bacterial Vaginosis Do Not Increase the Cure Rate in a Chinese Cohort
8
PubMed. Effects of probiotics for the treatment of bacterial vaginosis in adult women: a meta-analysis of randomized clinical trials
9
PubMed. Improved treatment of vulvovaginal candidiasis with fluconazole plus probiotic Lactobacillus rhamnosus GR-1 and Lactobacillus reuteri RC-14
10
Indonesian Journal of Obstetrics and Gynecology. Effectiveness of Oral Probiotics (Lactobacillus Rhamnosus Gr1 and Lactobacillus Reuteri RC14) as Adjuvant Therapy in Reproductive Aged Women with Vaginal Discharge
11
PubMed Central. The role of probiotics in women with recurrent urinary tract infections
12
Journal of Pediatric Urology. Probiotic lactobacillus reuteri RC-14 and lactobacillus rhamnosus GR-1 for prevention of urinary tract infections in catheterization-dependent girls with spina bifida
13
PubMed Central. Effect of Oral Probiotic Lactobacillus rhamnosus GR-1 and Lactobacillus reuteri RC-14 on the Vaginal Microbiota, Cytokines and Chemokines in Pregnant Women
14
Journal of Dairy Science. Urogenital Lactobacilli Probiotics, Reliability, and Regulatory Issues
15
PubMed Central. Randomized controlled trial of probiotics for the prevention of spontaneous preterm delivery associated with intrauterine infection: study protocol
16
FEMS Immunology & Medical Microbiology. Oral use of Lactobacillus rhamnosus GR-1 and L. fermentum RC-14 significantly alters vaginal flora: randomized, placebo-controlled trial in 64 healthy women
17
PubMed Central. Comparative Genomic and Phenotypic Analysis of the Vaginal Probiotic Lactobacillus rhamnosus GR-1
18
Scientific Reports. The lectin-like protein 1 in Lactobacillus rhamnosus GR-1 mediates tissue-specific adherence to vaginal epithelium and inhibits urogenital pathogens